392 related articles for article (PubMed ID: 28358330)
1. Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer.
Yokoi K; Yamashita K; Watanabe M
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28358330
[TBL] [Abstract][Full Text] [Related]
2. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
3. Methylated DNA and microRNA in body fluids as biomarkers for cancer detection.
Ma Y; Wang X; Jin H
Int J Mol Sci; 2013 May; 14(5):10307-31. PubMed ID: 23681012
[TBL] [Abstract][Full Text] [Related]
4. Early Epigenetic Markers for Precision Medicine.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic diagnostics of cancer--the application of DNA methylation markers.
Paluszczak J; Baer-Dubowska W
J Appl Genet; 2006; 47(4):365-75. PubMed ID: 17132902
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.
Goessl C; Krause H; Müller M; Heicappell R; Schrader M; Sachsinger J; Miller K
Cancer Res; 2000 Nov; 60(21):5941-5. PubMed ID: 11085508
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
9. Stool DNA methylation assays in colorectal cancer screening.
Kadiyska T; Nossikoff A
World J Gastroenterol; 2015 Sep; 21(35):10057-61. PubMed ID: 26401070
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic epigenetic biomarkers in cancer.
Costa-Pinheiro P; Montezuma D; Henrique R; Jerónimo C
Epigenomics; 2015; 7(6):1003-15. PubMed ID: 26479312
[TBL] [Abstract][Full Text] [Related]
11. Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.
Constâncio V; Nunes SP; Moreira-Barbosa C; Freitas R; Oliveira J; Pousa I; Oliveira J; Soares M; Dias CG; Dias T; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2019 Dec; 11(1):175. PubMed ID: 31791387
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer.
Hashimoto Y; Zumwalt TJ; Goel A
Epigenomics; 2016 May; 8(5):685-703. PubMed ID: 27102979
[TBL] [Abstract][Full Text] [Related]
13. Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients.
Guo Q; Song Y; Zhang H; Wu X; Xia P; Dang C
Med Oncol; 2013 Dec; 30(4):695. PubMed ID: 23963856
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation biomarkers and their utility for solid cancer diagnostics.
Heichman KA; Warren JD
Clin Chem Lab Med; 2012 Oct; 50(10):1707-21. PubMed ID: 23089699
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation biomarkers in biological fluids for early detection of respiratory tract cancer.
Markopoulou S; Nikolaidis G; Liloglou T
Clin Chem Lab Med; 2012 Oct; 50(10):1723-31. PubMed ID: 23089700
[TBL] [Abstract][Full Text] [Related]
16. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer.
Ng JM; Yu J
Int J Mol Sci; 2015 Jan; 16(2):2472-96. PubMed ID: 25622259
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic biomarkers in the blood of patients with urological malignancies.
Ellinger J; Müller SC; Dietrich D
Expert Rev Mol Diagn; 2015 Apr; 15(4):505-16. PubMed ID: 25719388
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers for cancer detection in blood and bodily fluids.
Feng Q; Yu M; Kiviat NB
Crit Rev Clin Lab Sci; 2006; 43(5-6):497-560. PubMed ID: 17050080
[TBL] [Abstract][Full Text] [Related]
20. Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer.
Stastny I; Zubor P; Kajo K; Kubatka P; Golubnitschaja O; Dankova Z
Clin Breast Cancer; 2020 Dec; 20(6):e711-e722. PubMed ID: 32792225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
